Residue Warning

Cattle intended for human consumption must not be slaughtered within 21 days of the last treatment. Do not use in female dairy cattle 20 months of age or older. Use of this drug product in these cattle may cause milk residues. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal.

Important Safety Information

Zuprevo: FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. TO AVOID ACCIDENTAL INJECTION, DO NOT USE IN AUTOMATICALLY POWERED SYRINGES WHICH HAVE NO ADDITIONAL PROTECTION SYSTEM. IN CASE OF HUMAN INJECTION, SEEK MEDICAL ADVICE IMMEDIATELY AND SHOW THE PACKAGE INSERT OR LABEL TO THE PHYSICIAN. Cattle intended for human consumption must not be slaughtered within 21 days of the last treatment. Do not use in female dairy cattle 20 months of age or older. Use of this drug product in these cattle may cause milk residues. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal. The effects of Zuprevo^®18% on bovine reproductive performance, pregnancy and lactation have not been determined. Swelling and inflammation, which may be severe, may be seen at the injection site after administration. Subcutaneous injection may result in local tissue reactions which persist beyond slaughter withdrawal period. This may result in trim loss of edible tissue at slaughter.

DO NOT USE Zuprevo^®18% IN SWINE. Fatal adverse events have been reported following the use of tildipirosin in swine. NOT FOR USE IN CHICKENS OR TURKEYS.

Contact

U.S. only: Merck Animal Health livestocktechsrvc@merck-animal-health.com or call 1-800-211-3574
For additional information, please see the product label.

References

1. Menge M. et al. Pharmacokinetics of tildipirosin in bovine plasma, lung tissue, and bronchial fluid (from live, non-anesthetized cattle). J Vet Pharm Ther. Doj: 10.1111/J. 1365-2885, 2011. 1349.x.
2. Wilhelm C (2009). Determination of the minimum inhibitory concentrations of 20, 23-di-piperidinyl-mycaminosyltylonlide against bacteria isolated from the respiratory tract of cattle suffering from respiratory disease isolated in different European countries between 2004 and 2008. Intervet-Doc. No. V-0045-0249.
3. Stratton CW (2005). Molecular mechanisms of action for antimicrobial agents: General principles and mechanisms for selected classes of antibiotics. In V Lorian (ed). Antibiotics in Laboratory Medicine. 5th ed., Lippincott Williams and Wilkins, Philadelphia, USA, pp. 547-549. Intervet-Doc. No. V-0045-0444.
4. Metz W (2005). Determination of the efficacy of P-MTMacrolide solution for injection in the treatment of experimentally induced Mannheimia haemolytica infection in cattle. Intervet-Doc. No. V-0045x-0017.